aldo-keto reductase family 1 member B15Genealiases: AKR1B10L · AKR1B10L · AK1R1B7 · AKR1R1B7
Q-omics provides the consensus-scored AKR1B15 profile across patient tissues and cancer cell-line models. AKR1B15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKR1B15 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, AKR1B15 RNA expression shows 11,504 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, HNSC, and ESCA as cancer lineages where AKR1B15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1B15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1B15 survival associations across molecular data types. AKR1B15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1B15 RNA expression–survival associations across cancer types. High AKR1B15 expression shows unfavorable associations in KIRC, UVM, BLCA, LIHC, KIRP and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKR1B15 RNA expression.
This table summarizes AKR1B15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for AKR1B15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1B15 shows lower tumor expression in COAD and higher tumor expression in HNSC, LUAD, LUSC, LIHC and BLCA. The HNSC box plot shows higher AKR1B15 RNA expression in tumor versus normal tissue (log2 FC = +1.773, t-test p < 0.001).
This table shows molecular features associated with AKR1B15 in patient tissues and cancer cell lines. In patient samples, AKR1B15 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR1B15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
